NAD Press Releases

NAD Refers Advertising for Obesity Research Council’s ‘Lipozene’ to FTC for Review after Advertiser Declines to Participate in NAD Proceeding

NAD has referred advertising for Lipozene, a product marketed by the Obesity Research Council, to the Federal Trade Commission (FTC) after the company declined to participate in NAD’s review of its advertising claims.

Read More

NAD Examines Fareportal’s Search Engine Marketing in Challenge Brought by Expedia

NAD has recommended that online travel agent Fareportal Inc. – operator of the CheapOair.com and OneTravel.com sites –discontinue certain claims in its search engine marketing as the claims could potentially mislead consumers when they appear in response to consumer searches.

Read More

Sumo Logic Discontinues Express, Implied Claims Challenged by Splunk

Sumo Logic, Inc., the maker of software for log management and analytic systems, has said it will discontinue all advertising claims challenged before the NAD by competitor Splunk, Inc.

Read More

NAD Recommends ADD-Care Discontinue Claims for Supplement Promoted for ‘Help’ with ADD, ADHD Symptoms

The NAD has recommended that ADD-care, the maker of the dietary supplement ADD-care, discontinue all claims for the product reviewed by NAD in a recent proceeding.

Read More

NAD Recommends AT&T Modify Certain ‘U-Verse’ Ads to Better Disclose Limitations of Service, Discontinue TV Spots; Finds Advertiser Provided ‘Reasonable Basis’ for Speed Claim

The NAD has recommended that AT&T Services, Inc., modify disclosures that accompany certain advertised Internet speed claims made for the company’s U-verse service.

Read More

NAD Recommends ‘LifeCaps’ Discontinue all Claims Challenged by CRN

The National Advertising Division has recommended that LifeCaps Neutraceuticals, LLC, discontinue all challenged advertising claims for the company’s “LifeCaps,” a dietary supplement promoted as a “survival pill.”

Read More